Aids was first identified 40 years ago: these are the game changers that have revolutionised treatment – and the obstacles ...

The Tampa Bay Times e-Newspaper is a digital replica of the printed paper seven days a week that is available to read on ...

Zacks Research increased their FY2024 earnings per share (EPS) estimates for Gilead Sciences in a note issued to investors on ...

The twice-yearly HIV prevention shot from Gilead Sciences has proven 100% effective in women and nearly as effective in men, ...

Gilead and Aelix first teamed up in 2018 for a clinical research collaboration agreement to investigate the vaccine.

GILD has put up a solid performance in the past six months on positive data readouts and strong quarterly results. We believe there is more room for growth, given GILD's strong fundamentals.

On Wednesday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $92.41 which represents a slight increase of $1.06 or 1.16% from the prior close of $91.35. The stock opened at ...

Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its ...

Gilead Sciences (GILD) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Lead PURPOSE researcher Moupali Das, Vice President, Clinical Development, HIV Prevention & Pediatrics, designed the PURPOSE ...

As the largest internal organ in the human body, the liver supports a wide range of responsibilities related to metabolism, ...

On Friday, Gilead Sciences, Inc. (GILD) stock saw a modest uptick, ending the day at $90.19 which represents a slight increase of $0.43 or 0.48% from the prior close of $89.76. The stock opened at $89 ...